Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2  J-ALTA study

ConclusionsIn the J-ALTA TKI-naive cohort, brigatinib demonstrated clinically meaningful efficacy consistent with the international phase 3 study. The safety profile in Japanese patients was consistent with previous studies. Brigatinib is an important first-line option for Japanese patients withALK-positive NSCLC.Clinical registrationNCT03410108
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research